Aggressive Systemic Mastocytosis — Trials

Aggressive Systemic Mastocytosis — Trials · CancerIndex

Clinical trials

Registered studies

9 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 1
Ph III recruiting: 0
Growth YoY: —
Industry share: 100%
Top sponsor: Cogent Biosciences, Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03580655	(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis	completed	Phase 2	107	Blueprint Medicines CorporationINDUSTRY	12	Apr 24, 2026	clinicaltrials
NCT02561988	(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies	completed	Phase 1	86	Blueprint Medicines CorporationINDUSTRY	2